Outcomes of the Intermountain study, which examined almost 1,000 patients over a 10-year-period, will exist virtually at the 2021 American College of Cardiologys Scientific Session on Monday, May 17.
” The advice to take Omega-3s for the good of your heart is pervasive, but previous studies have shown that science doesnt really back this up for every single omega-3,” stated Viet T. Le, MPAS, PA, scientist and cardiovascular doctor assistant at the Intermountain Heart Institute and principal private investigator of the research study. “Our findings show that not all Omega-3s are alike, which EPA and DHA integrated together, as they typically remain in supplements, might void the advantages that patients and their doctors want to attain.”
In this study, Intermountain scientists used the INSPIRE computer registry, an Intermountain Healthcare database began in 1993 that has more than 35,000 blood samples from nearly 25,000 clients.
Through INSPIRE, researchers determined 987 clients who underwent their very first recorded coronary angiographic research study at Intermountain Healthcare in between 1994 and 2012. From those blood samples, the flowing levels of EPA and DHA in their blood was determined. Scientist then tracked those patients for 10 years, searching for major cardiac adverse events, that included heart attack, stroke, heart failure needing hospitalization or death.
They discovered that patients with the highest levels of EPA had actually lowered risk of significant heart events. When examining how EPA and DHA affect one another, they discovered that greater DHA blunts the advantage of EPA. In particular, they also found that those clients with higher levels of DHA than EPA, were more at risk for heart problems.
Le said that these results raise additional issues about using combined EPA/DHA, especially through supplements.
” Based on these and other findings, we can still inform our clients to consume Omega-3 rich foods, but we should not be advising them in pill kind as supplements and even as combined (EPA + DHA) prescription products,” he stated. “Our information adds additional strength to the findings of the current REDUCE-IT (2018) study that EPA-only prescription items decrease cardiovascular disease events.”
Fulfilling: American College of Cardiology 2021
Other members of the research study group include: Stacey Knight; Kirk Knowlton; Raymond McCubrey; Jeramie D. Watrous; Mahan Najhawan; Khoi Dao; Tami Bair, Benjamin Horne; J. Brent Muhlestein; Donald Lappe; Madisyn Taylor; John Nelson; John Carlquist; Mohit Jain; and Jeffrey Anderson.
Doctors typically advise Omega-3s to help patients lower their cholesterol and enhance heart health. Those Omega-3s can originate from fatty fish like salmon and mackerel, or supplements that frequently contain a mix of the acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA).
Now, brand-new research study from the Intermountain Healthcare Heart Institute in Salt Lake City finds that higher EPA blood levels alone lowered the danger of significant cardiac events and death in clients, while DHA blunted the cardiovascular benefits of EPA. Higher DHA levels at any level of EPA, worsened health outcomes.
They found that clients with the highest levels of EPA had actually reduced threat of major heart occasions. When assessing how EPA and DHA impact one another, they discovered that higher DHA blunts the advantage of EPA. In particular, they also found that those patients with greater levels of DHA than EPA, were more at risk for heart problems.